Blockade of EGFR pathway by small molecule tyrosine kinase inhibitors (TKIs) has become the standard-of-care in patients with EGFR mutant non-small cell lung cancer (NSCLC) and defines a milestone of biomarker-based precision medicine [3]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.